USPTO’s most recent policy misstep occurred on May 14, with the USPTO Director’s precedential decision in Magnolia Medical Technologies v. Kurin. USPTO casts the decision as an effort to restore the Patent Trial and Appeal Board (PTAB) and Inter Partes Review (IPR) process to its congressional design.

It is the opposite. The decision offers a profoundly misleading account of the IPR process – one that distorts the legislative record, overrides congressional intent, and cloaks the real beneficiaries of USPTO policies (i.e., litigation speculators and NPEs) and the real victims (i.e., productive businesses targeted by NPEs).

Related:

• US: Advanced Manufacturing & Industrial Technology Coalition – Leaving USPTO Errors Uncorrected Weakens the US Patent System
• US: Advanced Manufacturing & Industrial Technology Coalition – USPTO Patent Policy Promotes Financial Speculation in USPTO’s Own Errors
• US: Advanced Manufacturing & Industrial Technology Coalition – USPTO Patent Policy Undermines US AI Leadership
• US: Advanced Manufacturing & Industrial Technology Coalition – USPTO Patent Policy Undermines SMEs
• US: Advanced Manufacturing & Industrial Technology Coalition – USPTO Patent Policy Undermines National Security
• US: Advanced Manufacturing & Industrial Technology Coalition – USPTO Patent Policy Undermines US Manufacturing
• US: Advanced Manufacturing and Industrial Technology Coalition – Letter to White House re US Patent Policy